Expression profiling of ion channel genes predicts clinical outcome in breast cancer

Molecular Cancer

Research

Eun A Ko¹  Hyoweon Bang²  Jae-Hong Ko²  Inja Lim²  Tong Zhou³  Wanjun Gu⁴ 

[1] Department of Medicine, University of California-San Francisco, 94143, San Francisco, CA, USA;Department of Physiology, College of Medicine, Chung-Ang University, 156-756, Seoul, South Korea;Institute for Personalized Respiratory Medicine, University of Illinois at Chicago, 60612, Chicago, IL, USA;Department of Medicine, University of Illinois at Chicago, 60612, Chicago, IL, USA;Research Center for Learning Sciences, Southeast University, 210096, Nanjing, Jiangsu, China;

关键词: Ion channel;    Breast cancer;    Gene expression;    p53;    Estrogen receptor;    Molecular signature;    Microarray;   

DOI  :  10.1186/1476-4598-12-106

 received in 2013-04-11, accepted in 2013-09-16,  发布年份 2013

来源: Springer

【 摘 要 】

BackgroundIon channels play a critical role in a wide variety of biological processes, including the development of human cancer. However, the overall impact of ion channels on tumorigenicity in breast cancer remains controversial.MethodsWe conduct microarray meta-analysis on 280 ion channel genes. We identify candidate ion channels that are implicated in breast cancer based on gene expression profiling. We test the relationship between the expression of ion channel genes and p53 mutation status, ER status, and histological tumor grade in the discovery cohort. A molecular signature consisting of ion channel genes (IC30) is identified by Spearman’s rank correlation test conducted between tumor grade and gene expression. A risk scoring system is developed based on IC30. We test the prognostic power of IC30 in the discovery and seven validation cohorts by both Cox proportional hazard regression and log-rank test.Results22, 24, and 30 ion channel genes are found to be differentially expressed with a change in p53 mutation status, ER status, and tumor histological grade in the discovery cohort. We assign the 30 tumor grade associated ion channel genes as the IC30 gene signature. We find that IC30 risk score predicts clinical outcome (P < 0.05) in the discovery cohort and 6 out of 7 validation cohorts. Multivariate and univariate tests conducted in two validation cohorts indicate that IC30 is a robust prognostic biomarker, which is independent of standard clinical and pathological prognostic factors including patient age, lymph node status, tumor size, tumor grade, estrogen and progesterone receptor status, and p53 mutation status.ConclusionsWe identified a molecular gene signature IC30, which represents a promising diagnostic and prognostic biomarker in breast cancer. Our results indicate that information regarding the expression of ion channels in tumor pathology could provide new targets for therapy in human cancers.

【 授权许可】

Unknown   
© Ko et al.; licensee BioMed Central Ltd. 2013. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.